Sequential Analysis of Development of Invasive Thyroid Follicular Cell Carcinomas in Inflamed Capsular Regions of Rats Treated with Sulfadimethoxine after N-bis(2-hydroxypropyl)nitrosamine-initiation
Free accessResearch articleFirst published online February, 2004
Sequential Analysis of Development of Invasive Thyroid Follicular Cell Carcinomas in Inflamed Capsular Regions of Rats Treated with Sulfadimethoxine after N-bis(2-hydroxypropyl)nitrosamine-initiation
A 2-stage thyroid follicular carcinogenesis model in rats initiated with N-bis(2-hydroxypropyl)nitrosamine (DHPN) is widely used to detect modifying effects of chemicals on thyroid carcinogenesis. A number of goitrogens are known to strongly promote carcinogenesis, and the carcinomas often originate adjacent to the thyroid capsule and show invasive growth into the capsule or adjacent tissues. To clarify mechanisms of progression to invasive carcinomas, we sequentially evaluated histopathological and immunohistochemical characteristics of thyroids in male F344 rats treated with sulfadimethoxine (SDM, 0.1% in drinking water) for 0—10 weeks beginning 1 week after DHPN initiation (2800 mg/kg body weight, single s.c. injection). In DHPN-SDM-treated rats, multiple focal hyperplasias and adenomas developed in thyroid follicular parenchyma at weeks 4 to 6. Apart from the proliferative lesions, capsular thickening with inflammatory cell infiltration, mainly consisting of macrophages, and migration of follicular epithelium into the capsule were also observed. Focal hyperplasias/adenomas adjacent to the capsule progressively developed to invasive carcinomas at weeks 6 to 10. In thyroid parenchyma, malignant lesions were seldom observed. With SDM-treatment alone, although no neoplastic lesions were observed, capsular thickening with inflammation and epithelial migration resulted in intracapsular residual follicles. Intracapsular residual follicular cells as well as invasive and intrathyroidal carcinoma cells generally showed increased cell proliferative activity, coincidental with cytoplasmic/nuclear positivity for β-catenin. These results suggested that β -catenin activation related to capsular inflammation may play a role in development of invasive carcinomas but is insufficient for tumor formation by itself. Whether this is associated with mutations in the β-catenin gene remains to be clarified.
Berg, D.J., Davidson, N., Kühn, R., Müller, W., Menon, S., Holland, G., Thompson-Snipes, L., Leach, M.W., and Rennick, D. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses . J Clin Invest98, 1010—20.
2.
Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., Knuechel, R., and Kirchner, T. (2001). Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA98, 10356—61.
3.
Bohni, E., Fust, B., Rieder, J., Schaerer, K., and Havas, L. (1969). Comparative toxicological, chemotherapeutic and pharmacokinetic studies with sulphormethoxine and other sulphonamides in animals and man. Chemotherapy14, 195—226.
4.
Capen, C.C. (1997). Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol25, 39—48.
5.
Coussens, L.M., and Werb, Z. (2002). Inflammation and cancer. Nature420, 860—7.
6.
Dashwood, R.H., Suzui, M., Nakagama, H., Sugimura, T., and Nagao, M. (1998). High frequency of β-catenin (ctnnb1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. Cancer Res58, 1127—9.
7.
Fujimoto, N., Sakai, Y., and Ito, A. (1992). Increase in estrogen receptor levels in MNU-induced thyroid tumors in LE rats. Carcinogenesis13, 1315—8.
8.
Garcia-Rostan, G., Camp, R.L., Herrero, A., Carcangiu, M.L., Rimm, D.L., and Tallini, G. (2001). β-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol158, 987—96.
9.
Hardisty, J.F., and Boorman, G.A. (1990). Thyroid gland. In Pathology of the Fischer Rat, Reference and Atlas (G. A. Boorman, S. L. Eustis, M. R. Elwell, C. A. Montgomery, Jr., and W. F. MacKenzie, eds.), pp. 519—36. Academic Press, San Diego, California.
10.
He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, P.J., Vogelstein, B., and Kinzler, K.W. (1998). Identification of c-MYC as a target of the APC pathway. Science281, 1509—12.
11.
Hiasa, Y., Kitahori, Y., Kato, Y., Ohshima, M., Konishi, N., Shimoyama, T., Sakaguchi, Y., Hashimoto, H., Minami, S., and Murata, Y. (1987). Potassium perchlorate, potassium iodide, and propylthiouracil: promoting effect on the development of thyroid tumors in rats treated with N-bis(2-hydroxypropyl)-nitrosamine. Jpn J Cancer Res (Gann)78, 1335— 40.
12.
Hsu, S.M., Raine, L., and Fanger, H. (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem29, 577—80.
13.
Kim, D.J., Han, B.S., Ahn, B., Hasegawa, R., Shirai, T., Ito, N., and Tsuda, H. (1997). Enhancement by indole-3-carbinol of liver and thyroid gland neoplastic development in a rat medium-term multiorgan carcinogenesis model. Carcinogenesis18, 377—81.
14.
Kitahori, Y., Hiasa, Y., Konishi, N., Enoki, N., Shimoyama, T., and Miyashiro, A. (1984). Effect of propylthiouracil on the thyroid tumorigenesis induced by N-bis(2-hydroxypropyl)nitrosamine in rats. Carcinogenesis5, 657—60.
15.
Kitahori, Y., Naito, H., Konishi, N., Ohnishi, T., Shirai, T., and Hiasa, Y. (1995). Frequent mutations of Ki-ras codon 12 inN-bis (2-hydroxypropyl)-nitrosamine-initiated thyroid, kidney and lung tumors in Wistar rats. Cancer Lett96, 155—61.
16.
Kobayashi, Y., Kawaoi, A., and Katoh, R. (2002). Mutation of ras oncogene in di-isopropanolnitrosamine-induced rat thyroid carcinogenesis. Virchows Arch441, 289—95.
17.
McClain, R.M. (1989). The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol Pathol17, 294—306.
18.
Mishra, A., Mishra, S.K., Agarwal, A., Das, B.K., Agarwal, G., and Gambhir, S. (2002). Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area. World J Surg . 26, 153—7.
19.
Mitsumori, K., Onodera, H., Takahashi, M., Shimo, T., Yasuhara, K., Kitaura, K., Takahashi, M., and Hayashi, Y. (1995). Effect of thyroid stimulating hormone on the development and progression of rat thyroid follicular cell tumors. Cancer Lett92, 193—202.
20.
Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K.W. (1997). Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science275, 1787—90.
21.
Okada, F., Kawaguchi, T., Habelhah, H., Kobayashi, T., Tazawa, H., Takeichi, N., Kitagawa, T., and Hosokawa, M. (2000). Conversion of human colonic adenoma cells to adenocarcinoma cells through inflammation in nude mice. Lab Invest80, 1617—28.
22.
Omholt, K., Platz, A., Ringborg, U., and Hansson, J. (2001). Cytoplasmic and nuclear accumulation of β-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma . Int J Cancer92, 839—42.
23.
Pitot, H.C., and Dragan, Y.P. (1991). Facts and theories concerning the mechanisms of carcinogenesis. FASEB J5, 2280—6.
24.
Pötter, E., Bergwitz, C., and Brabant, G. (1999). The cadherin-catenin system: Implications for growth and differentiation of endocrine tissues. Endocr Rev20, 207—39.
25.
Resnik, E. (1997). β-catenin—one player, two games. Nat Genet16, 9—11.
26.
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997). Stabilization of β-catenin by genetic defects in melanoma cell lines. Science275, 1790—2.
27.
Santelli, G., de Franciscis, V., Portella, G., Chiappetta, G., D'Alessio, A., Califano, D., Rosati, R., Mineo, A., Monaco, C., Manzo, G., Pozzi, L., and Vecchio, G. (1993). Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter. Cancer Res53, 5523—7.
28.
Santoro, M., Thomas, G.A., Vecchio, G., Williams, G.H., Fusco, A., Chiappetta, G., Pozcharskaya, V., Bogdanova, T.I., Demidchik, E.P., Cherstvoy, E.D., Voscoboinik, L., Tronko, N.D., Carss, A., Bunnell, H., Tonnachera, M., Parma, J., Dumont, J.E., Keller, G., Hofler, H., and Williams, E.D. (2000). Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer82, 315—22.
29.
Smith, K., Bui, T.D., Poulsom, R., Kaklamanis, L., Williams, G., and Harris, A.L. (1999). Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer. Br J Cancer81, 496—502.
30.
Suzui, M., Ushijima, T., Dashwood, R.H., Yoshimi, N., Sugimura, T., Mori, H., and Nagao, M. (1999). Frequent mutations of the rat β-catenin gene in colon cancers induced by methylazoxymethanol acetate plus 1-hydroxyanthraquinone . Mol Carcinog24, 232—7.
31.
Takahashi, M., Fukuda, K., Sugimura, T., and Wakabayashi, K. (1998). β-catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res58, 42—6.
32.
Tetsu, O., and McCormick, F. (1999). β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature398, 422—6.
33.
Tsuda, H. (1996). Goiter, nodular hyperplasia, adenoma, and carcinoma of the thyroid induced by amitrole and ethylenethiourea, rat. In Endocrine System, Second Edition (T. C. Jones, C. C. Capen, and U. Mohr, eds.), pp. 274—80. Springer-Verlag , Berlin, Germany.
34.
Tsujiuchi, T., Tsutsumi, M., Sasaki, Y., Murata, N., and Konishi, Y. (2000). Mutations of adenomatous polyposis coli and β-catenin genes during progression of lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Cancer Res60, 6611—6.
35.
von Wasielewski, R., Rhein, A., Werner, M., Scheumann, G.F.W., Dralle, H., Pötter, E., Brabant, G., and Georgii, A. (1997). Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res57, 2501—7.
